BDBM267424 US10688100, Compound 14::US10966985, Compound 14::US9718822, 14::US9750744, Example 14::US9902741, Example 14

SMILES Fc1cnc2OCCOC(=O)c3cnn4ccc(nc34)N3CCC[C@@H]3c2c1

InChI Key InChIKey=NCZKBNXMSRBQNT-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 267424   

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 55nMpH: 7.5Assay Description:An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkA kinase activity in the presence of inhibitors. Immulon 4HBX 384-well microtiter ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2018
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 55nMAssay Description:An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkA kinase activity in the presence of inhibitors. Immulon 4HBX 384-well microtiter ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 55nMAssay Description:An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkA kinase activity in the presence of inhibitors Immulon 4HBX 384-well microtiter p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 28.9nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 107nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 30.3nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 7.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 28.9nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 107nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 30.3nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 7.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent